

Supplemental Table 2. Summary of adverse events by treatment group (percentages and 95% CI).

Adverse Events (AEs) Categories	Treatment Group		Total 95% CI	p-value
	Placebo n=92 95% CI	NAC n=81 95% CI		
Any Infection	20% 11% - 28%	20% 10% - 29%	20% 13% - 26%	0.975
Any Rash	2% 0% - 6%	2% 0% - 6%	2% 0% - 5%	>0.999*
Any Bronchospasm	1% 0% - 4%	1% 0% - 4%	1% 0% - 3%	>0.999*
Any Arrhythmia	10% 3% - 16%	9% 2% - 15%	9% 5% - 14%	0.796
Nausea/Vomiting	4% 0% - 9%	14% 6% - 22%	9% 4% - 13%	0.031
Any Other	9% 2% - 15%	11% 4% - 19%	10% 5% - 15%	0.594

Number of AE Categories for each patient (0-6)	Treatment Group		Total 95% CI	p-value
	Placebo n=92 95% CI	NAC n=81 95% CI		
0	59% 48% - 69%	58% 47% - 69%	58.4% 51% - 66%	0.122
1	38% 28% - 49%	30% 19% - 40%	34% 27% - 41%	
2	2% 0% - 6%	10% 3% - 17%	6% 2% - 10%	
	1% 0% - 4%	2% 0% - 6%	2% 0% - 4%	
3				

*Fisher's Exact Test

No differences were observed between the groups, with the exception of nausea and vomiting which was more common in the treated group.